[go: up one dir, main page]

FI20030932A7 - Menetelmä cis-FTC:n enantiomeerien erottamiseksi - Google Patents

Menetelmä cis-FTC:n enantiomeerien erottamiseksi Download PDF

Info

Publication number
FI20030932A7
FI20030932A7 FI20030932A FI20030932A FI20030932A7 FI 20030932 A7 FI20030932 A7 FI 20030932A7 FI 20030932 A FI20030932 A FI 20030932A FI 20030932 A FI20030932 A FI 20030932A FI 20030932 A7 FI20030932 A7 FI 20030932A7
Authority
FI
Finland
Prior art keywords
ftc
cis
separating enantiomers
enantiomers
separating
Prior art date
Application number
FI20030932A
Other languages
English (en)
Swedish (sv)
Inventor
Dennis C Liotta
Raymond F Schinazi
Woo-Baeg Choi
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35276919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI20030932(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/659,760 external-priority patent/US5210085A/en
Application filed by Univ Emory filed Critical Univ Emory
Publication of FI20030932A7 publication Critical patent/FI20030932A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
FI20030932A 1991-02-22 2003-06-24 Menetelmä cis-FTC:n enantiomeerien erottamiseksi FI20030932A7 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/659,760 US5210085A (en) 1990-02-01 1991-02-22 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US73608991A 1991-07-26 1991-07-26
US83115392A 1992-02-12 1992-02-12
PCT/US1992/001339 WO1992014743A2 (en) 1991-02-22 1992-02-20 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane

Publications (1)

Publication Number Publication Date
FI20030932A7 true FI20030932A7 (fi) 2003-06-24

Family

ID=35276919

Family Applications (2)

Application Number Title Priority Date Filing Date
FI933684A FI114915B (fi) 1991-02-22 1993-08-20 Menetelmä terapeuttisesti käyttökelpoisten beta-2-hydroksimetyyli-5-(5-fluorisytosin-1-yyli)-1,3-oksatiolaanin enantiomeerien valmistamiseksi
FI20030932A FI20030932A7 (fi) 1991-02-22 2003-06-24 Menetelmä cis-FTC:n enantiomeerien erottamiseksi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI933684A FI114915B (fi) 1991-02-22 1993-08-20 Menetelmä terapeuttisesti käyttökelpoisten beta-2-hydroksimetyyli-5-(5-fluorisytosin-1-yyli)-1,3-oksatiolaanin enantiomeerien valmistamiseksi

Country Status (24)

Country Link
EP (3) EP0575482A1 (fi)
JP (2) JP2901160B2 (fi)
KR (1) KR0172590B1 (fi)
CN (4) CN1037682C (fi)
AT (2) ATE270291T1 (fi)
AU (2) AU679649B2 (fi)
BG (1) BG62053B1 (fi)
BR (1) BR9205661A (fi)
CA (2) CA2104399C (fi)
CZ (1) CZ295074B6 (fi)
DE (2) DE69233786D1 (fi)
DK (2) DK1439177T3 (fi)
ES (2) ES2345102T3 (fi)
FI (2) FI114915B (fi)
HU (2) HU227823B1 (fi)
IE (1) IE920545A1 (fi)
IL (1) IL100965A (fi)
MX (1) MX9200747A (fi)
MY (1) MY114350A (fi)
NO (3) NO312399B1 (fi)
NZ (2) NZ241625A (fi)
PT (1) PT100151B (fi)
RO (2) RO122814B1 (fi)
WO (1) WO1992014743A2 (fi)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
CA2152269C (en) * 1989-02-08 1999-09-21 Bernard Belleau (Deceased) Process for preparing substituted 1,3-oxathiolanes with antiviral properties
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
WO1993023021A2 (en) * 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
GB9320316D0 (en) * 1993-10-01 1993-11-17 Smithkline Beecham Plc Pharmaceuticals
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
FR2720397B1 (fr) * 1994-05-24 1996-08-23 Laphal Laboratoires Sa Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
AU722214B2 (en) * 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
JP2000515852A (ja) * 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
EA005097B1 (ru) 1997-03-19 2004-10-28 Эмори Юниверсити Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гепатита-b
IT1290447B1 (it) 1997-03-28 1998-12-03 Zambon Spa Derivati 1,3-ossatiolanici ad attivita' antivirale
WO1998044913A2 (en) 1997-04-07 1998-10-15 Triangle Pharmaceuticals, Inc. Compositions containing mkc-442 in combination with other antiviral agents
WO1999037754A2 (en) * 1998-01-26 1999-07-29 Pharm-Eco Laboratories, Inc. Enzyme activated supports for enantiomeric separations
EA200700564A1 (ru) 1998-02-25 2007-08-31 Эмори Юниверсити 2`-фторнуклеозиды
RU2244712C2 (ru) * 1998-08-12 2005-01-20 Гайлид Сайенсиз, Инк. Способ получения 1,3-оксатиоланового нуклеозида, способ получения производного 1,3-оксатиоланил-5-она
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
DE69912842T2 (de) 1998-12-23 2004-05-13 Shire Biochem Inc., Laval Antivirale nukleosidanaloga
KR100339786B1 (ko) * 1999-04-02 2002-06-07 안용현 라세미 혼합물 상태로 존재하는 뉴클레오시드로부터 거울상 이성질체의 분리 방법
EP1634888A3 (en) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
CA2426187C (en) 2000-10-18 2011-08-16 Pharmasset Limited Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
US6828119B2 (en) * 2001-01-04 2004-12-07 Bristol Myers Squibb Company Enzymatic deprotection of amines and hydroxides
DE10104231A1 (de) 2001-01-31 2002-08-08 Consortium Elektrochem Ind Verfahren zur enzymatischen Herstellung von enantiomerenreinen 1,3-Dioxolan-4-on-Derivaten
DK1574512T3 (da) 2001-03-01 2008-03-03 Abbott Lab Polymorfe og andre krystallinske former af cis-FTC
AU2008202336B2 (en) * 2001-03-01 2011-11-10 Abbvie Inc. Polymorphic and other crystalline forms of cis-FTC
WO2003087119A1 (en) * 2002-04-12 2003-10-23 Achillion Pharmaceuticals, Inc. METHOD FOR SYNTHESIZING β-L-FLUORO-2´,3´DIDEHYDROCYTIDINE (β-L-FD4C)
WO2004048590A1 (en) * 2002-11-18 2004-06-10 Shire Biochem Inc. Stereoselective process for the production of dioxolane nucleoside analogues
JP4996241B2 (ja) 2003-01-14 2012-08-08 ギリアード サイエンシーズ， インコーポレイテッド 組み合わせ抗ウイルス治療のための組成物および方法
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
MX2007011274A (es) * 2005-03-14 2008-03-13 Shire Canada Inc Procesos y metodos para la preparacion de cis-2-hidroximetil-4-(ci tosin-1-il)-1,3-oxatiolano opticamente activas o sales aceptables farmaceuticamente del mismo.
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
PL2144604T3 (pl) 2007-02-28 2012-02-29 Conatus Pharmaceuticals Inc Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830
AU2008265397C1 (en) 2007-06-18 2013-08-29 Sunshine Lake Pharma Co., Ltd. Bromo-phenyl substituted thiazolyl dihydropyrimidines
WO2009084033A2 (en) 2007-12-07 2009-07-09 Matrix Laboratories Limited Process for producing 5-fluoro-1-(2r,5s)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yi]cytosine
WO2009107692A1 (ja) * 2008-02-29 2009-09-03 株式会社カネカ ２’－水酸基が保護されたリボヌクレオシド誘導体およびその製造方法
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
EP2377862A1 (en) 2010-03-29 2011-10-19 Esteve Química, S.A. Process for obtaining emtricitabine
WO2011123668A2 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Stereoselective synthesis of phosphorus containing actives
EA201691695A1 (ru) 2010-11-19 2017-11-30 Джилид Сайэнс, Инк. Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат
WO2013167743A1 (en) 2012-05-11 2013-11-14 Akron Molecules Gmbh Use of compounds for the treatment of pain
CA2889903C (en) 2012-10-29 2021-03-09 Manjinder Singh Phull Antiviral phosphonate analogues and process for preparation thereof
CN102911167B (zh) * 2012-11-09 2014-06-25 合肥工业大学 一种高光学纯度的核苷类中间体的制备方法
CN104059057A (zh) * 2014-01-03 2014-09-24 石家庄龙泽制药有限公司 拉米夫定杂质3-tu的制备方法
CN108285895B (zh) * 2018-01-26 2020-06-23 中国科学院南海海洋研究所 一种酯酶EstC11及其编码基因和应用
KR102069443B1 (ko) 2018-08-31 2020-01-22 (주)대한뷰티산업진흥원 울금, 비트 및 무 추출물을 포함하는 바이오셀룰로오스 및 이의 제조방법
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
JP2023542455A (ja) * 2020-07-14 2023-10-10 スーチュワン ユニバーシティ ３－デオキシ－２－ケトアルドン酸窒素含有誘導体、その製造方法及びその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
WO1992008717A1 (en) * 1990-11-13 1992-05-29 Biochem Pharma Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
CA2105486C (en) 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides

Also Published As

Publication number Publication date
JP2901160B2 (ja) 1999-06-07
CZ295074B6 (cs) 2005-05-18
AU8077398A (en) 1998-10-15
FI114915B (fi) 2005-01-31
EP0984013B1 (en) 2004-06-30
CN1084745C (zh) 2002-05-15
MX9200747A (es) 1992-09-01
NZ241625A (en) 1996-03-26
NO932980L (no) 1993-08-20
KR0172590B1 (ko) 1999-02-01
CN1109108C (zh) 2003-05-21
EP1439177A1 (en) 2004-07-21
IE920545A1 (en) 1992-08-26
AU679649B2 (en) 1997-07-03
ATE469147T1 (de) 2010-06-15
RO122814B1 (ro) 2010-02-26
MY114350A (en) 2002-10-31
ES2345102T3 (es) 2010-09-15
NO312399B1 (no) 2002-05-06
CN1203232A (zh) 1998-12-30
FI933684L (fi) 1993-09-06
EP0984013A3 (en) 2000-08-02
BG62053B1 (bg) 1999-01-29
AU1561792A (en) 1992-09-15
CA2104399C (en) 2005-10-18
EP0984013A2 (en) 2000-03-08
IL100965A (en) 1999-12-31
CN1065065A (zh) 1992-10-07
ATE270291T1 (de) 2004-07-15
PT100151A (pt) 1993-05-31
NO2005015I1 (no) 2005-07-11
DE69233379T2 (de) 2005-07-14
DK1439177T3 (da) 2010-08-02
CN1418966A (zh) 2003-05-21
JPH10147586A (ja) 1998-06-02
NZ250842A (en) 1996-03-26
HUT65548A (en) 1994-06-28
FI933684A0 (fi) 1993-08-20
ES2224547T3 (es) 2005-03-01
EP0575482A1 (en) 1993-12-29
CN1037682C (zh) 1998-03-11
CA2513440C (en) 2010-11-30
BR9205661A (pt) 1994-05-24
EP1439177B1 (en) 2010-05-26
WO1992014743A3 (en) 1992-10-29
BG98062A (bg) 1994-04-29
CN100396785C (zh) 2008-06-25
NO932980D0 (no) 1993-08-20
HU211344A9 (en) 1995-11-28
DE69233379D1 (de) 2004-08-05
JP3292830B2 (ja) 2002-06-17
WO1992014743A2 (en) 1992-09-03
NO2005015I2 (no) 2007-10-01
JPH06508605A (ja) 1994-09-29
DK0984013T3 (da) 2004-10-25
CA2513440A1 (en) 1992-09-03
NO2008010I1 (no) 2008-07-07
RO119365B1 (ro) 2004-08-30
IL100965A0 (en) 1992-11-15
CA2104399A1 (en) 1992-08-23
CN1127301A (zh) 1996-07-24
AU3794395A (en) 1996-03-14
PT100151B (pt) 1999-09-30
HU227823B1 (en) 2012-03-28
HU9302377D0 (en) 1993-11-29
AU665187B2 (en) 1995-12-21
DE69233786D1 (de) 2010-07-08
HK1026419A1 (en) 2000-12-15
CZ49792A3 (en) 1993-03-17

Similar Documents

Publication Publication Date Title
FI20030932A7 (fi) Menetelmä cis-FTC:n enantiomeerien erottamiseksi
FI905284A0 (fi) Menetelmä kiinnirullauksessa
FI942161L (fi) Menetelmä 5-metyyli-tetrahydrofoolihapon erottamiseksi
NO953043D0 (no) Fremgangsmåte for syntetisere acetotriglyceridfett
FI951596L (fi) Menetelmä 10-desasetyylibakkatiini-III:n saamiseksi
FI875655L (fi) Menetelmä kromatograafiseksi erottamiseksi
FI884279L (fi) Menetelmä amidin valmistamiseksi mikrobiologisesti
TR25002A (tr) Kristalik natrinyumsilikatlarin hazirlanis yöntemi
NO179531C (no) Fremgangsmåte for brönnbehandling
DE69130277D1 (de) Verfahren zur trennung optischer isomere
FI945441A7 (fi) Uusi menetelmä 7beta-substituoitu-4-atsa-5alfa-androstan-3-onien valmi stamiseksi
DK0568590T3 (da) Fremgangsmåde til malkning
FI902889A7 (fi) Menetelmä amiinien erottamiseksi
FI952585A7 (fi) Menetelmä bentsopyraaniyhdisteiden valmistamiseksi
DK0455155T3 (da) Adskillelse af enantiomere af cimaterol
FI942907A7 (fi) Menetelmä lipaasin valmistamiseksi
FI921621L (fi) Sprutmetod foer braensle
DK719788A (da) Fremgangsmaade til fremstilling af vancomycin
NO179932C (no) Fremgangsmåte for separering av fluidkomponenter
FI101530B1 (fi) Menetelmä sulfaatin erottamiseksi
DK0549134T3 (da) Fremgangsmåde til udskæring
BR9102112A (pt) Metodo de fabricacao de ziperes
FI951656A7 (fi) Menetelmä enantiomeerien erottamiseksi raseemisesta seoksesta
FI933079A7 (fi) Entsymaattinen menetelmä delta-valerolaktonien raseemisten seosten erottamiseksi
FI892144A7 (fi) Menetelmä 5-C-hydroksimetyylialdoheksoosipohjaisten yhdisteiden valmistamiseksi